瑞士制药巨头诺华集团（Novartis）周四上调了其中期销售预期，目前预计到2028年的年增长率为6%，原因是已上市药物的强劲势头和即将上市药物的前景。
该公司此前的中期目标是2023年至2028年经汇率调整后的销售额增长至少5%。
然而，该公司表示，鉴于其在2024年的强劲表现，仍预计2024-2029年期间每年的销售额将增长5%。
诺华将于周四举行一场投资者活动，该公司重申，到2027年，其核心利润率目标至少为40%。
该公司还上调了五种具有数十亿美元销售潜力的药物的最高年销售额估计，这五种药物是：Cosentyx、Kisqali、Kesimpta、Pluvicto和Leqvio。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.